Dr. Chan received his BS and MS degrees in Engineering from UCLA, a Master of Science degree in Medical Radiological Physics, and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training in pathology at the Harvard Medical School and the Dana-Farber Cancer Institute. In 1987, Dr. Gerald Chan co-founded Morningside, a diversified investment group engaged in private equity and venture capital investments in North America, Asia and Europe. Morningside has been an active investor in China since 1992.

Dr. Chan is a director of publicly listed Hang Lung Group Limited, a Hong Kong-based property holding company. He serves on the boards of several biotechnology companies in North America and Europe including Stealth Peptides, Advanced Cell Diagnostics, Matrivax, Vaccine Technologies Inc., and Oxyrane. He is a member of the Global Advisory Council of the International Society for Stem Cell Research, the International Board of Governors of the New York Academy of Sciences, the Board of Trustees of Fudan University in Shanghai, the Global Advisory Council of Harvard University, and chairs the Board of Overseers of the Morningside College of the Chinese University of Hong Kong.